After an IVIG Infusion: Headache, Chills and Tiredness, and When to Contact Your Team

The infusion chair is finally empty, the cannula is out, and you are home with a cup of tea you did not really want. Then, somewhere around bedtime, a dull pressure builds behind your eyes. You feel cold under two blankets. Tomorrow you had planned to go back to work, and now you are wondering whether this is normal or the start of something you should be worried about.

If you have just had intravenous immunoglobulin, this scene is familiar to a lot of people. Immunoglobulin is the medical word for antibodies, the proteins your immune system uses to recognize threats, and IVIG is a concentrated pool of those antibodies collected from thousands of healthy plasma donors and given through a vein. It has been used for decades, and its aftermath is well described. Knowing the pattern of IVIG side effects, what to expect and what falls outside the ordinary is the difference between a rough night and a frightened one.

This explainer walks through the typical first 72 hours, the mechanisms behind each symptom, the rare problems that matter, and the specific signs that should prompt a call rather than a wait.

IVIG side effects: what to expect in the first 24 hours

Most reactions to intravenous immunoglobulin are what clinicians call infusion-related: they show up while the drip is running or within the first day, and they are usually mild. MedlinePlus lists headache, chills, fever, flushing, muscle or joint aches, nausea, fatigue and a rise or fall in blood pressure among the effects patients commonly report. Nurses watch for exactly these things, which is why your pulse, temperature and blood pressure are checked repeatedly during the first infusion and often at every subsequent one.

Timing tells you a lot. A reaction during the infusion itself, such as flushing, a racing heart or a sudden chill, is often linked to the speed at which the antibodies are entering the bloodstream. Slowing or pausing the drip is the standard first response, and many people feel better within minutes once the rate drops. Symptoms that arrive later, in the evening or the next morning, tend to be the achy, flu-like kind and are more about the body’s inflammatory response to a large load of foreign protein.

What most people do not expect is how ordinary the picture usually is. A headache that feels like a tension headache, a couple of hours of shivering, a night of poor sleep and a day of feeling wrung out is a common story. Vomiting, a rash that spreads quickly, wheezing or feeling faint are not part of that ordinary picture and are the reason infusion units keep emergency medicines close by.

Two practical points shape the first day. Drink fluids steadily unless your team has told you to restrict them, because dehydration makes both headache and kidney strain more likely. And plan for a quiet evening; people who try to power through a full schedule after a first infusion often describe the fatigue as harder than the headache.

How does IVIG actually work in the body?

Immunoglobulin G, or IgG, is the most abundant antibody in your blood. A single IVIG preparation contains IgG pooled from a very large number of donors, purified and treated to remove or inactivate viruses, then concentrated into a solution. When it is infused, your bloodstream is suddenly carrying a much higher level of antibody than it did an hour earlier, and that surge is used for two quite different jobs.

The first job is replacement. In people whose immune systems cannot make enough antibody, such as those with certain primary immunodeficiency disorders, the donated antibodies simply stand in for the missing ones and help fight bacteria and viruses. This is why replacement therapy is repeated regularly: IgG is broken down over weeks, so the level drifts down and has to be topped up.

The second job is immune modulation, and it is less intuitive. In autoimmune and inflammatory conditions, the immune system is attacking the body’s own tissues, nerves in Guillain-Barré syndrome or platelets in immune thrombocytopenia, for example. A high dose of pooled antibody appears to dampen that attack through several mechanisms at once: it can block the receptors that immune cells use to destroy antibody-coated cells, mop up harmful antibodies and inflammatory proteins, and shift the balance of signaling molecules. Researchers still debate which mechanism matters most in which disease.

The same features that make IVIG useful also explain its side effects. Delivering a large volume of protein into the circulation raises blood thickness, or viscosity, which is part of why headache, fluid shifts and, rarely, clots occur. Traces of other donor proteins and antibodies can trigger inflammatory or allergic responses. And because the product is derived from human plasma, screening and viral inactivation steps are a fixed part of its manufacture. Understanding this makes the pattern of reactions feel less random.

Who is IVIG usually for, and who is asked to wait?

Intravenous immunoglobulin is prescribed in three broad settings. Replacement for people who cannot make adequate antibodies, which includes several inherited immunodeficiency disorders and some acquired ones. Immune modulation in autoimmune conditions, where the NHS and Mayo Clinic describe IVIG as a first-line option for Guillain-Barré syndrome and a treatment used in immune thrombocytopenia when platelet counts need to rise quickly or when other options are unsuitable. And a longer list of neurological, dermatological and rheumatological conditions where guideline support varies from strong to limited and the decision is made case by case.

The people asked to wait, or to have a different plan, are usually those in whom the known risks weigh heavier. MedlinePlus flags several groups for particular caution: people with existing kidney disease, diabetes, heart disease or a history of blood clots; those who are dehydrated, older, or immobile; and people with a past severe reaction to immunoglobulin. A history of a specific antibody deficiency called IgA deficiency also matters, because some people with it have antibodies against IgA and can react to the small amounts present in many preparations. None of these automatically rules out treatment. They change the product chosen, the rate, the monitoring and sometimes the route.

Route is the other fork in the road. The same antibody can be given under the skin as subcutaneous immunoglobulin, in smaller and more frequent amounts. Because it enters the bloodstream slowly, the whole-body effects such as headache, chills and fatigue tend to be milder, while local swelling and redness at the needle site become the main complaint. People who struggle with infusion reactions or with vein access are sometimes moved to this route, but that is a clinical decision that depends on the condition being treated and the dose needed, and it belongs to the prescribing team.

Why does IVIG cause a headache, and how long does it usually last?

Headache is the complaint people mention first, and it comes in two versions that are worth telling apart.

The common version is a pressure-type or migraine-like headache that starts during the infusion or within hours of it and usually fades over one to two days. Several things feed it. The volume of protein-rich fluid raises the thickness of the blood and changes fluid balance around the brain. Inflammatory signaling molecules released in response to the foreign protein sensitize pain pathways much as they do in a viral illness. Dehydration, a fast infusion rate, a first-ever infusion and a personal history of migraine all make it more likely. People who already live with migraine often say IVIG brings on their usual pattern, sometimes with light sensitivity and nausea.

The uncommon version is aseptic meningitis, and understanding it is the single most useful piece of knowledge for anyone on IVIG. Meningitis means inflammation of the membranes around the brain and spinal cord; aseptic means no infection is involved. In this case the irritation is chemical, caused by the immunoglobulin itself. MedlinePlus describes it as typically beginning within hours to about two days after an infusion, with a severe headache, stiff neck, sensitivity to light, fever, nausea and vomiting. It is frightening, it is uncomfortable, and it needs same-day assessment because the symptoms overlap with infectious meningitis. The reassuring part is that it usually resolves within days once the infusion is stopped, without lasting harm, and it is often prevented on future cycles by a slower rate, more fluid or a different preparation.

The practical distinction is severity and neck stiffness. A headache you can function through, that responds to rest, fluids and whatever simple pain relief your team has approved, is the common kind. A headache that is the worst you have had, that makes bending your neck forward painful, or that comes with vomiting and a dislike of light, is the kind that gets a phone call.

Chills, fever and flu-like aching: what is happening

Shivering under a blanket in a warm room is one of the more disorienting IVIG experiences, and it has a straightforward explanation. When large amounts of donor protein arrive in the bloodstream, immune cells release signaling molecules called cytokines, the same messengers that make you feel wretched during a bout of influenza. Cytokines reset the body’s thermostat upward. Your brain now believes your normal temperature is too low, so you feel cold and start shivering to generate heat, and a modest fever often follows. Muscle and joint aches, a general heaviness and loss of appetite travel with the same chemistry.

This is not an infection, and it is not a sign the treatment has failed. It is a predictable inflammatory response, more common during a first infusion, at higher rates and with larger total volumes. It typically peaks within the first several hours and settles within a day. Infusion nurses recognize rigors, the medical word for violent shivering, and will usually pause the infusion, warm you up and reassess before deciding whether to restart at a slower rate.

Where it becomes a judgment call is fever in someone whose immune system is already weak. If you receive IVIG because you cannot make enough antibodies, you are also more prone to real infections, and a fever the day after an infusion could be either. Many immunology teams give patients a threshold above which any fever should be reported regardless of timing, and it is worth knowing yours. A fever that starts more than a day after the infusion, keeps climbing, or comes with a cough, urinary symptoms, or pain in one specific place is less likely to be an infusion reaction.

Flushing, a warm red face and chest, belongs in this family too. Alone, it is usually benign and rate-related. Combined with itching, hives, swelling of the lips or throat, or wheezing, it moves into allergic territory, which is treated very differently and is why the drip is always stopped first and questions asked second.

Fatigue after an IVIG infusion: the day-after heaviness

Tiredness after IVIG is under-discussed in clinic and over-experienced at home. Patients describe it in almost identical terms: like the day after a bad flu, or a hangover without the fun part. It usually arrives the evening of the infusion or the following morning, is heaviest on the first day after, and lifts gradually over two or three days. Some people on long-term replacement therapy notice a milder, recurring dip in the day or two after each cycle and a slow return of energy through the middle of the interval.

Several mechanisms overlap. The cytokine surge that causes chills also produces what researchers call sickness behavior, a coordinated response in which the body conserves energy, sleeps more and does less. Hours in a chair with an intravenous line, often with limited food and disrupted sleep the night before, add a simple physical toll. Antihistamines, if your team uses them before the infusion to lower the chance of an allergic-type reaction, cause drowsiness in their own right. And for many people the underlying condition, whether it is a neuromuscular illness or a chronic immune deficiency, already sets a low baseline that the infusion temporarily lowers further.

The honest answer to how long it lasts is that the common pattern is days, not weeks. Fatigue that persists well beyond the first week, gets worse rather than better, or arrives with new shortness of breath, unusual pallor, a yellow tinge to the skin or eyes, or dark urine is not typical post-infusion tiredness and should be reported. Those particular companions can point to hemolysis, the breakdown of red blood cells, which is discussed later and which is a recognized, if uncommon, delayed effect.

Practically, most people learn to schedule infusions before a lighter day, to eat properly beforehand, and to treat the following afternoon as recovery time rather than a sign of weakness. Gentle movement helps more than lying still all day, and it also matters for clot prevention.

Common versus rare IVIG reactions: a comparison table

Grouping reactions by how often they occur, when they usually start and what they mean helps put a rough evening into perspective. The table below reflects the categories described in MedlinePlus drug information and major clinical references. Frequencies are described in words rather than percentages because they vary substantially by product, dose, rate and the condition being treated.

Reaction	How common	Typical onset	What it usually means	Typical response
Headache, chills, mild fever, aches, nausea, fatigue	Common	During infusion to the next day	Rate-related or inflammatory reaction	Slower rate, fluids, rest; team-approved simple pain relief
Flushing, blood pressure changes, fast heartbeat	Fairly common	During infusion	Usually rate-related	Pause or slow the drip, observe
Hives, itching, wheeze, lip or throat swelling	Uncommon	During infusion, sometimes shortly after	Allergic-type reaction; can be severe	Stop infusion, emergency treatment, product review
Aseptic meningitis (severe headache, stiff neck, light sensitivity)	Uncommon	Hours to about 2 days after	Chemical irritation of the brain’s membranes	Same-day assessment; usually resolves in days
Hemolysis (breakdown of red cells: dark urine, pallor, jaundice, fatigue)	Rare	Days after, sometimes up to a week or more	Donor antibodies reacting with recipient blood group	Blood tests, monitoring, product change
Blood clots (leg swelling, chest pain, breathlessness, stroke signs)	Rare	Hours to days after	Increased blood viscosity plus risk factors	Emergency care
Kidney injury (little urine, swelling, sudden weight gain)	Rare	Days after	Strain on kidney filters, historically linked to certain stabilizers	Urgent blood tests and review

Two things stand out from the table. Almost everything in the top rows is uncomfortable and self-limiting. Almost everything in the bottom rows is rare but has a recognizable signature, and those signatures are what the final section of this article is built around. Knowing the pattern turns a vague worry into a specific question you can put to your team.

What the days and weeks after IVIG usually look like

A rough timeline helps set expectations, with the caveat that individual experiences vary widely and none of these ranges is a promise.

The infusion day itself is dominated by the procedure. A first infusion is usually run more slowly and monitored more closely than later ones, and it can take several hours. Reactions that happen here are mostly rate-related and are handled in the chair. By evening, the inflammatory symptoms may be building: the headache, the chill, the sense of having been run over.

Day one after the infusion is typically the low point for fatigue and aching. The headache is often still present but easing. This is also the window in which aseptic meningitis, if it is going to happen, generally declares itself, so a headache that is worsening rather than plateauing on this day deserves attention rather than another dose of patience.

Days two and three usually bring a steady lift. Most people are back to their baseline energy and free of headache by the end of this window. Delayed effects that surface here are the ones to know about: dark or tea-colored urine, unusual pallor or breathlessness on stairs, or passing far less urine than normal. These are uncommon but they are the reasons your team may ask you to come in for blood tests if something feels off later in the week.

Beyond the first week, the picture depends on why you are being treated. In Guillain-Barré syndrome, the NHS describes IVIG as a course given over several days during the acute illness, and recovery of nerve function is measured in weeks to months rather than days, driven by the nerves healing rather than by the infusion. In immune thrombocytopenia, Mayo Clinic notes that IVIG can raise platelet counts quickly, but the effect is usually temporary, lasting a matter of weeks, which is why it is often used to cover a bleeding risk or a procedure while longer-term treatment is planned. In antibody replacement, the pattern simply repeats every few weeks, and most people find their reactions become more predictable, and often milder, with each cycle.

How to reduce IVIG side effects: hydration, rate and premedication

Three levers do most of the work in making IVIG more tolerable, and all three sit with your infusion team rather than with you at home.

Rate comes first. The speed at which the antibody solution enters your vein is the single most adjustable factor in infusion-related reactions. Teams start slowly, increase in steps if you are tolerating it, and keep a record of the rate at which you did well so that later infusions can be planned around it. If you have had a rough time previously, it is entirely reasonable to ask whether the maximum rate can be capped lower or the total volume spread over more time or more days.

Hydration comes second. Being well hydrated before, during and after the infusion dilutes the viscosity effect, supports the kidneys and reduces headache. Some units give intravenous fluids alongside the immunoglobulin for people who have had headaches or who carry kidney or clot risk factors. At home, steady fluid intake over the following day is the simplest thing most people can do, unless a heart or kidney condition means your team has set a fluid limit.

Premedication comes third. Premedication means medicines given before the infusion to blunt an expected reaction, typically a simple pain reliever such as acetaminophen, an antihistamine, or in some cases a corticosteroid, a class of anti-inflammatory drug. Whether you receive any of these, and which, is a prescribing decision that weighs your reaction history against the drowsiness and other effects of the premedicines themselves. It is not something to add or adjust on your own, and it is worth telling your team if the antihistamine leaves you too sleepy to function, because there may be alternatives.

Two further options exist for people who continue to struggle. A change of product matters because preparations differ in concentration, stabilizers and IgA content, and someone who reacts to one may tolerate another. A change of route to subcutaneous immunoglobulin, described earlier, trades whole-body reactions for local ones. Both are conversations for the clinic, not decisions for the kitchen table.

Rare but serious risks: clots, kidney strain, hemolysis and aseptic meningitis

The serious risks of IVIG are uncommon, but they are consistent enough that regulators require them to be highlighted in product information, and MedlinePlus lists each one plainly. They are described here in the same spirit: not to alarm, but so that the signs are recognizable.

Blood clots, or thrombosis, are the risk most emphasized. Concentrated antibody raises blood viscosity, and in someone who is older, dehydrated, immobile, taking estrogen-containing medicines, or already prone to clots, that can tip the balance toward a clot forming in a leg vein, a lung artery, the heart or the brain. The signs are those of any clot: a swollen, painful or warm leg; chest pain or sudden breathlessness; and sudden weakness, numbness, facial drooping or trouble speaking. These are emergency signs. Reducing the risk is part of why teams ask about your clot history, hydrate you, and encourage you to move around rather than lie still after an infusion.

Kidney injury has become less common since manufacturers moved away from certain sugar-based stabilizers, but it has not vanished, particularly in people with existing kidney disease or diabetes. Passing much less urine than usual, unexplained swelling of the ankles or face, or rapid weight gain over a couple of days are the signals, and they call for prompt blood tests.

Hemolysis is the breakdown of red blood cells, caused when antibodies in the donor pool react with the recipient’s own blood group markers. It is more likely with higher doses and in people with certain blood groups. It tends to appear days after the infusion, sometimes up to a week or more, with fatigue out of proportion to the usual pattern, pallor, breathlessness, a yellow tinge to the skin or whites of the eyes, and dark urine. Blood tests confirm it, and most cases are mild, but some need treatment and product changes.

Aseptic meningitis was covered in the headache section and is included here because it belongs in the same conversation: uncommon, alarming, usually short-lived, and always worth a same-day call. The unifying message is that each of these has a signature, and none of them looks like ordinary post-infusion tiredness.

Does IVIG affect vaccines, driving, work and exercise?

These are the everyday questions that rarely make it into the consent conversation, and they have reasonably clear answers.

Vaccines are the most important. IVIG is a bath of ready-made antibodies, and those antibodies can neutralize the weakened viruses in live vaccines before your immune system gets a chance to respond, blunting the vaccine’s effect. For this reason immunology guidance, including CDC vaccine recommendations, advises that live vaccines such as measles-mumps-rubella and varicella be spaced apart from immunoglobulin, often by many months depending on the dose given. Inactivated vaccines, including most influenza and pneumococcal vaccines, are not neutralized in the same way, though in people receiving IVIG for antibody deficiency the response to any vaccine may be limited by the underlying condition. Tell whoever gives you a vaccine that you receive immunoglobulin, and tell your immunology team before booking one.

Driving is a matter of judgment on the day. If you have had an antihistamine as premedication, or if you are dizzy, headachy or unusually sleepy, you should not drive home. Many units ask first-time patients to arrange a lift regardless. On subsequent days, the question is simply whether you feel alert enough; there is no fixed rule.

Work and study are usually possible within a day or two, though people commonly protect the day after the infusion. If you can, book infusions ahead of a lighter day rather than a demanding one. Employers do not need clinical detail, but a predictable pattern of a recovery day every few weeks is easier to plan around when it is explained once.

Exercise is encouraged in gentle forms. Walking after an infusion supports circulation and lowers clot risk. Intense exertion on the same day, particularly in heat, adds dehydration to viscosity and is better postponed until you are eating and drinking normally and the headache has gone. Your own condition, especially if it affects muscles or nerves, sets the real limit, and your team is the right source for what is safe.

IVIG side effects: what to expect over repeat infusions

For people on long-term treatment, the more useful question is not what happens once but what happens over a year of infusions. The pattern most clinicians describe, and most patients recognize, is that the first infusion or two are the most unpredictable and that reactions become both milder and more familiar once a tolerated rate, product and premedication plan have been found. This is not guaranteed, but it is common enough that a difficult first experience should not be read as a forecast.

Some effects do behave differently with repetition. The whole-body inflammatory reaction, the chills and aching, tends to ease. Headache is more persistent as a recurring complaint, especially in people with migraine, and is the reason many long-term patients eventually discuss route or product changes. Fatigue in the day or two after each cycle often settles into a predictable dip that people learn to schedule around. Local vein irritation can become an issue when the same veins are used repeatedly, which is one reason some patients and teams discuss a longer-term access device or a switch to the subcutaneous route.

Repeat exposure also means repeat monitoring. Teams typically check kidney function and blood counts periodically, both because of the rare risks described earlier and because the conditions IVIG treats need tracking in their own right. Keeping a simple record after each infusion, noting the rate reached, any reaction, when it started and when it eased, gives your team far better information than memory does at the next appointment. Several patients describe this log as the thing that finally got their headache pattern taken seriously and adjusted.

A last point about expectations. Side effects and treatment effect are separate. Feeling terrible after an infusion does not mean it is working harder, and feeling nothing does not mean it is not working. The effect on your condition is measured by your symptoms and your blood tests over weeks, not by the size of your headache that night.

What people often get wrong about IVIG

A handful of misunderstandings come up again and again in infusion units, and correcting them saves a lot of unnecessary worry.

It is a blood transfusion. It is derived from blood plasma, but it is a purified protein product, not whole blood or red cells. There is no matching of blood type, and the viral screening and inactivation steps are more extensive than for a standard transfusion. The residual, very small risk of transmitting infection is monitored and reported, and it is not the main safety concern with modern preparations.

A reaction means you are allergic. Most reactions are inflammatory or rate-related, not allergic. True allergy, with hives, swelling or wheeze, is uncommon. Calling a headache an allergy can lead to unnecessary avoidance of a treatment that a slower rate would have made tolerable.

Bad side effects mean strong treatment. There is no link between how ill an infusion makes you feel and how well it treats your condition. Feeling fine afterwards is not a sign the product is weak.

You can keep going as normal. A first infusion in particular deserves a quiet evening, planned fluids and no driving if premedication has made you drowsy. Treating it as a routine appointment is how people end up feeling worse than they needed to.

It is the same product every time. Preparations differ in concentration, stabilizers and IgA content, and supply pressures sometimes lead to substitutions. If your infusion feels different, ask whether the product changed; it is a legitimate and common explanation.

IVIG fixes the underlying condition. In autoimmune disease it dampens the attack; in immunodeficiency it replaces what is missing. It treats and controls, it does not repair the immune system, which is why treatment is repeated and why other therapies often run alongside it. Understanding that keeps expectations realistic and makes the recurring commitment easier to live with.

Questions to ask your care team

Consent conversations are often rushed, and the questions that matter to daily life are the ones that get left out. Taking a short list into the appointment changes that. These are the ones experienced patients and infusion nurses most often wish had been asked earlier.

• What rate did I tolerate last time, and is that recorded so the next infusion starts from it rather than from a default?
• Which premedications, if any, am I receiving, what are they for, and are there alternatives if one leaves me too drowsy to function?
• Do I have any personal risk factors for clots, kidney strain or hemolysis, and does that change how I am monitored or hydrated?
• What fever threshold should I report regardless of how soon after the infusion it occurs, given my underlying condition?
• How should I contact you out of hours, and which symptoms should send me to emergency care rather than to the clinic line?
• Is there a symptom diary or log you would like me to keep between infusions, and what would you most like recorded?
• Are any vaccines due, and how should they be timed around my infusions?
• If my headaches continue despite rate changes, what are the next options, including a different preparation or the subcutaneous route?
• How will we know whether the treatment is working for my condition, and over what timeframe should I expect to see that?
• Are there any activities, medicines or supplements you would like me to avoid on infusion day or the day after?

None of these questions challenges the plan. They give the team the information it needs to tailor the plan to you, and they give you a clear map of what is normal, what to log and what to escalate. Writing down the answers, or asking whether you can record the conversation, means you are not relying on a tired memory that evening.

When to call your doctor

The ordinary aftermath of IVIG is uncomfortable but not dangerous: a manageable headache, chills, low-grade fever, aching and a day or two of fatigue that steadily improve. The signs below fall outside that pattern and should prompt a call to your care team the same day, or emergency care where indicated, rather than waiting to see how the night goes.

Seek emergency care immediately for: chest pain or pressure; sudden shortness of breath; sudden weakness or numbness on one side, facial drooping, slurred speech or confusion; hives with swelling of the lips, tongue or throat, wheezing or difficulty breathing; fainting or near-fainting. These can indicate a blood clot in the lungs, heart or brain, or a severe allergic reaction.

Contact your team the same day for: a severe headache, especially with a stiff or painful neck, sensitivity to light, or vomiting, which may indicate aseptic meningitis; a swollen, painful or warm calf or thigh; dark, tea-colored or reddish urine, unusual pallor, a yellow tinge to the skin or eyes, or breathlessness on mild effort in the days after the infusion, which may point to hemolysis; passing far less urine than usual, or new swelling of the ankles, hands or face, which can signal kidney strain; a fever above the threshold your team has given you, or any fever that starts more than a day after the infusion or keeps rising.

Mention at your next contact: headache, fatigue or aching that lasts well beyond three days; reactions that are clearly worse than at previous infusions; redness, pain or swelling at the cannula site that is spreading; or anything that simply feels different from your usual pattern.

When in doubt, call. Infusion teams would far rather hear about a headache that turns out to be ordinary than miss the one that is not. Every decision about slowing, changing or continuing your treatment belongs with the clinicians who know your history, and a timely phone call is how you give them the chance to make it well.

Frequently asked questions

How long does an IVIG headache usually last?

The common IVIG headache usually eases within one to two days, often improving with fluids, rest and any simple pain relief your team has approved. A headache that becomes severe, worsens on the day after the infusion, or arrives with a stiff neck, light sensitivity or vomiting is not the common kind and may indicate aseptic meningitis, which needs same-day assessment even though it usually resolves within days.

Is fatigue after an IVIG infusion normal, and how long does it last?

Yes, tiredness is one of the most commonly reported effects, usually heaviest the day after the infusion and lifting over two to three days. It reflects the inflammatory response to a large protein load, a long day in a chair and sometimes drowsy premedication. Fatigue that persists well beyond the first week, or that comes with pallor, dark urine, jaundice or breathlessness, should be reported because it can signal hemolysis.

What are the symptoms of IVIG aseptic meningitis?

Aseptic meningitis after IVIG typically causes a severe headache, a stiff or painful neck, sensitivity to light, fever, nausea and vomiting, beginning within hours to about two days after the infusion. It is a chemical irritation rather than an infection, and it usually settles within days, but because it overlaps with infectious meningitis it always needs same-day medical assessment and should be reported to your team.

How can I reduce IVIG side effects before my next infusion?

The main levers are a slower infusion rate, good hydration before and after, and premedication chosen by your team, such as a simple pain reliever, an antihistamine or in some cases a corticosteroid. If reactions persist, a change of preparation or a switch to subcutaneous immunoglobulin are options your clinicians may discuss. All of these are decisions for the prescribing team; do not add or change medicines on your own.

Why do I get chills and a fever after IVIG?

Large amounts of donor protein trigger release of signaling molecules called cytokines, which reset the body’s temperature setpoint upward. You feel cold, shiver to generate heat, and a modest fever may follow, often with aching. This is an inflammatory response, not an infection, and it usually settles within a day. If you receive IVIG for an antibody deficiency, ask your team what fever threshold should always be reported.

Can IVIG cause blood clots?

Yes, rarely. Concentrated antibody raises blood viscosity, and in people who are older, dehydrated, immobile, on estrogen-containing medicines or with a clot history, that can contribute to a clot in a leg vein, lung, heart or brain. Chest pain, sudden breathlessness, a swollen painful leg, or stroke-like weakness or speech changes are emergency signs. Hydration and gentle movement after an infusion are part of reducing the risk.

Does IVIG affect vaccines?

It can. The ready-made antibodies in IVIG may neutralize the weakened viruses in live vaccines such as measles-mumps-rubella and varicella, so these are spaced apart from immunoglobulin, often by many months depending on the dose. Inactivated vaccines are not neutralized in the same way, although the response may be limited by an underlying immune deficiency. Tell anyone giving you a vaccine that you receive immunoglobulin, and check timing with your team.

Can I drive or go to work after an IVIG infusion?

Do not drive on the infusion day if you have had an antihistamine premedication or feel dizzy, headachy or unusually sleepy; many units advise a lift for first infusions regardless. Most people can return to work or study within a day or two, though many protect the day after as recovery time. Gentle walking is encouraged, while intense exercise is better postponed until you are eating, drinking and feeling normal.

Do IVIG side effects get better with repeat infusions?

Often, though not always. The first infusion or two are usually the most unpredictable; once a tolerated rate, product and premedication plan are found, chills and aching tend to ease and reactions become more familiar. Headache can be more persistent, especially in people with migraine, and is a common reason for later discussions about a different preparation or the subcutaneous route. Keeping a log after each infusion helps your team adjust.

What is the difference between IVIG and subcutaneous immunoglobulin?

Both deliver the same pooled antibody. IVIG goes into a vein in larger amounts every few weeks, which makes whole-body effects such as headache, chills and fatigue more likely. Subcutaneous immunoglobulin goes under the skin in smaller, more frequent amounts, so those effects tend to be milder while local swelling and redness at the needle site become the main complaint. Which route suits you depends on your condition and is a decision for your treating team.

References

• MedlinePlus: Guillain-Barré Syndrome
• NHS: Guillain-Barré syndrome, Treatment

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.